Generali Investments Management Co LLC Buys Shares of 10,537 Veeva Systems Inc. (NYSE:VEEV)

Generali Investments Management Co LLC acquired a new stake in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 10,537 shares of the technology company's stock, valued at approximately $2,215,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of Veeva Systems by 72.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company's stock worth $25,000 after purchasing an additional 50 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Veeva Systems in the 4th quarter valued at about $25,000. Smithfield Trust Co increased its stake in shares of Veeva Systems by 145.5% in the fourth quarter. Smithfield Trust Co now owns 135 shares of the technology company's stock valued at $27,000 after buying an additional 80 shares during the period. True Wealth Design LLC raised its position in shares of Veeva Systems by 3,375.0% during the third quarter. True Wealth Design LLC now owns 139 shares of the technology company's stock worth $29,000 after acquiring an additional 135 shares during the last quarter. Finally, Retirement Wealth Solutions LLC acquired a new position in shares of Veeva Systems in the fourth quarter worth approximately $31,000. Institutional investors own 88.20% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on VEEV shares. Mizuho assumed coverage on shares of Veeva Systems in a research report on Wednesday, December 4th. They set an "outperform" rating and a $275.00 target price for the company. Royal Bank of Canada increased their price objective on shares of Veeva Systems from $275.00 to $285.00 and gave the stock an "outperform" rating in a research report on Friday, December 6th. Piper Sandler boosted their target price on shares of Veeva Systems from $280.00 to $290.00 and gave the company an "overweight" rating in a report on Friday, December 6th. Stifel Nicolaus lifted their price objective on Veeva Systems from $240.00 to $272.00 and gave the stock a "buy" rating in a research report on Friday, December 6th. Finally, StockNews.com raised Veeva Systems from a "hold" rating to a "buy" rating in a research note on Monday, February 17th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $256.52.

Remove Ads

Veeva Systems Trading Up 0.5 %

Shares of VEEV traded up $1.13 during trading hours on Friday, reaching $236.98. 1,192,386 shares of the stock traded hands, compared to its average volume of 1,010,716. Veeva Systems Inc. has a 52 week low of $170.25 and a 52 week high of $258.93. The stock has a fifty day simple moving average of $229.24 and a 200 day simple moving average of $222.22. The company has a market cap of $38.47 billion, a price-to-earnings ratio of 58.51, a PEG ratio of 1.89 and a beta of 0.88.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.